Literature DB >> 24510053

WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications.

Aliza Gardenswartz1, Rami I Aqeilan.   

Abstract

The WW domain-containing oxidoreductase (WWOX) gene, encodes a tumor suppressor located on 16q23.1, spanning FRA16D, one of the most active common fragile sites in the human genome, that is altered in numerous types of cancer. WWOX's alteration in these myriad cancers is due to disparate mechanisms including loss of heterozygosity, homozygous deletion and epigenetic changes. In vitro, WWOX has been found to be reduced or absent in numerous cancer cell lines and WWOX restoration has been found to inhibit tumor cell growth and invasion. Wwox knockout mice developed femoral focal lesions resembling osteosarcomas within one month of their life and aging Wwox heterozygous mice have an increased incidence of spontaneous lung and mammary tumors as well as B-cell lymphomas. We herein review WWOX's role that has been unearthed thus far in different types of malignancies, its clinical significance and future implications.

Entities:  

Keywords:  WW domain-containing oxidoreductase; breast cancer; hypermethylation; lung cancer; tumor suppressor gene

Mesh:

Substances:

Year:  2014        PMID: 24510053     DOI: 10.1177/1535370213519213

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  40 in total

Review 1.  Structural insights into the functional versatility of WW domain-containing oxidoreductase tumor suppressor.

Authors:  Amjad Farooq
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

Review 2.  Interplay between genetic and epigenetic factors governs common fragile site instability in cancer.

Authors:  Efrat Ozeri-Galai; Michal Tur-Sinai; Assaf C Bester; Batsheva Kerem
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 3.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

Review 4.  Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.

Authors:  Shin-Yi Liu; Ming-Fu Chiang; Yu-Jen Chen
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-27

Review 5.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

6.  WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma.

Authors:  Sara Del Mare; Hussam Husanie; Ortal Iancu; Mohammad Abu-Odeh; Konstantinos Evangelou; Francesca Lovat; Stefano Volinia; Jonathan Gordon; Gail Amir; Janet Stein; Gary S Stein; Carlo M Croce; Vassilis Gorgoulis; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2016-08-22       Impact factor: 12.701

Review 7.  WWOX: a fragile tumor suppressor.

Authors:  Morgan S Schrock; Kay Huebner
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-22

8.  Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.

Authors:  Mohammad Abu-Odeh; Tomer Bar-Mag; Haiming Huang; TaeHyung Kim; Zaidoun Salah; Suhaib K Abdeen; Marius Sudol; Dana Reichmann; Sachdev Sidhu; Philip M Kim; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

Review 9.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

10.  Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation.

Authors:  M Abu-Remaileh; R I Aqeilan
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.